A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

AI-assisted imaging improved prostate cancer diagnosis and biopsy decision-making in new research presented at EAU 2026.

EAU26: prostate cancer screening compares favourably compared to breast cancer in identifying significant cancers and reducing mortality.

Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

A prostate cancer committee has been accused of exaggerating the risks of screening. Advisers to Wes Streeting, the Health Secretary, rejected calls to offer targeted testing in November, arguing that ...

Apalutamide in patients with metastatic hormone-sensitive prostate cancer: Real-world experience and a retrospective multicenter analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Prostate cancer screening saves many more lives than earlier studies suggested, research shows. The results from the longest-running European trial show one life saved for every six men diagnosed, a ...

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...